Back to Trials
NCT06066502PHASE3Recruiting

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

Beth Israel Deaconess Medical Center

Start Date

6/24/2024

Completion Date

12/31/2030

Summary

The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.

Detailed Description

ARDS is a devastating condition that places a heavy burden on public health resources. Recent changes in the practice of mechanical ventilation have improved survival in ARDS, but mortality remains unacceptably high. This application is for support of a phase III multi-centered, randomized controlled trial of mechanical ventilation, directed by driving pressure and esophageal manometry, in patients with ARDS. The primary hypothesis is that precise ventilator titration to maintain lung stress within 0-12 centimeters of water (cm H2O), the normal physiological range experienced during relaxed breathing, will improve 60-day mortality, compared to guided usual care. Specific Aim 1: To determine the effect on mortality of the precision ventilation strategy, compared to guided usual care, in patients with ARDS. • Hypothesis 1: The precision ventilation strategy will decrease 60-day mortality (primary trial endpoint). Specific Aim 2: To evaluate the effects on lung injury of the precision ventilation strategy, compared to guided usual care, in patients with ARDS. * Hypothesis 2a: The precision ventilation strategy will improve clinical pulmonary recovery, defined using the composite endpoint alive and ventilator-free (AVF). * Hypothesis 2b: The precision ventilation strategy will attenuate alveolar epithelial injury. Specific Aim 3: To evaluate the hemodynamic safety profile of the precision ventilation strategy, compared to guided usual care, in patients with ARDS. • Hypothesis 3: The precision ventilation strategy will decrease hemodynamic instability, measured as shock-free days through Day 14.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Age ≥ 18 years 2. Ventilator-dependent ARDS, with all of the following (a-e): 1. Invasive ventilation with positive end-expiratory pressure (PEEP) ≥ 8 cm H2O or FiO2 ≥ 0.5 2. Hypoxemia as characterized by: • If arterial blood gas (ABG) available: the partial pressure of oxygen in the arterial blood (PaO2)/FiO2 ≤ 300 mm Hg, or, • if ABG not available OR overt clinical deterioration in oxygenation since last ABG: SpO2/FiO2 ≤ 316 with SpO2 ≤ 97% (both conditions) on two representative assessments between 1 to 6 hours apart. • If patient is positioned prone or receiving inhaled pulmonary vasodilator at time of screening: Qualifying PaO2/FiO2 or SpO2/FiO2 (as defined above) that was recorded within the 6 hours immediately prior to initiating either of these therapies may be used for eligibility determination. • If PEEP has been increased by \> 5 cm H2O within the last 12 hours immediately prior to screening: Qualifying PaO2/FiO2 or SpO2/FiO2 (as defined above) prior to PEEP increase may be used for eligibility determination if recorded within this 12-hour window. 3. Bilateral lung opacities on chest imaging not fully explained by effusions, lobar collapse, or nodules 4. Respiratory failure not fully explained by heart failure or fluid overload 5. Onset within 1 week of clinical insult or new/worsening symptoms 3. Early in ARDS course * Full criteria for ARDS (#2 above) first met within previous 3 days * Current invasive ventilation episode not more than 4 days duration * Current severe hypoxemic episode (receipt of invasive ventilation, noninvasive ventilation, or high-flow nasal cannula) not more than 10 days duration Exclusion Criteria: 1. Esophageal manometry already in use clinically 2. Severe brain injury: including suspected elevated intracranial pressure, cerebral edema, or Glasgow coma score (GCS) ≤ 8 directly caused by severe brain injury (e.g., ischemia or hemorrhage) 3. Gross barotrauma or chest tube inserted to treat barotrauma (note: chest tube inserted strictly for drainage of pleural effusion is not an exclusion) 4. Esophageal pathology that, in judgement of the site investigator, significantly increases risk of esophageal catheter placement, including high-risk esophageal varices, recent oropharyngeal or gastroesophageal surgery; or past esophagectomy 5. Ongoing severe coagulopathy (platelet \< 5000/μL or INR \> 4) 6. Extracorporeal membrane oxygenation (ECMO) or CO2 removal (ECCO2R) 7. Neuromuscular disease that impairs spontaneous breathing (including but not limited to amyotrophic lateral sclerosis, Guillain-Barré syndrome, spinal cord injury at C5 or above) 8. Any of the following severe chronic lung diseases: cystic fibrosis, acute bronchiectasis exacerbation, acute exacerbation of a chronic interstitial lung disease (ILD), chronic pulmonary hypertension (PH) on PH-targeted vasoactive medication, or lung transplant 9. End-stage chronic cirrhosis with Child-Pugh Class C (Section 12.3) 10. ICU admission for burn injury 11. Current ICU stay \> 2 weeks or acute care hospital stay \> 4 weeks 12. Moribund patient not expected to survive 24 hours as assessed by the study physician; if cardiopulmonary resuscitation (CPR) was provided, assessment for moribund status must occur at least 6 hours after CPR was completed 13. Current limitation on life-sustaining care (other than do-not-resuscitate), or expectation by clinical team that a limitation on life-sustained care will be adopted within next 24 hours. 14. Treating clinician refusal or unwilling to use protocol-specified ventilator settings/modes 15. Prisoner 16. Previous enrollment in this trial

Interventions

OTHER

Precision ventilation

OTHER

Guided usual care ventilation

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Respiratory Distress SyndromeRespiratory Failure

Locations

University of Arizona

Tucson, Arizona 85724

United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas 72205

United States

University of California, San Diego

La Jolla, California 92093

United States

University of California, Los Angeles Medical Center

Los Angeles, California 90024

United States

Cedar-Sinai Medical Center

Los Angeles, California 90048

United States

Stanford University

Palo Alto, California 94305

United States

University of California, San Francisco

San Franciso, California 94143

United States

University of Miami

Miami, Florida 33136

United States

Emory University / Grady Health System

Atlanta, Georgia 30322

United States

University of Chicago

Chicago, Illinois 60637

United States

Tufts Medical Center

Boston, Massachusetts 02111

United States

Massachusetts General Hospital

Boston, Massachusetts 02114

United States

Brigham and Women's Hospital

Boston, Massachusetts 02115

United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts 02215

United States

Lowell General Hospital

Lowell, Massachusetts 01854

United States

University of Michigan

Ann Arbor, Michigan 48109

United States

Mayo Clinic

Rochester, Minnesota 55905

United States

NYU Lagone Health

New York, New York 02114

United States

New York City Health + Hospitals/ Bellevue

New York, New York 10016

United States

Albert Einstein College of Medicine/Montefiore Medical Center

The Bronx, New York 10461

United States

Duke University Medical Center

Durham, North Carolina 27710

United States

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina 27157

United States

University of Cincinnati

Cincinnati, Ohio 45267

United States

Cleveland Clinic Foundation

Cleveland, Ohio 44195

United States

Ohio State University Wexner Medical Center

Columbus, Ohio 43210

United States

University of Oklahoma Health Sciences

Oklahoma City, Oklahoma 73104

United States

Oregon Health & Science University

Portland, Oregon 97239

United States

Thomas Jefferson University

Philadelphia, Pennsylvania 19107

United States

Baylor College of Medicine / St. Luke's Medical Center

Houston, Texas 77030

United States

Intermountain Health

Murray, Utah 84107

United States

University of Utah

Salt Lake City, Utah 84132

United States

University of Virginia

Charlottesville, Virginia 22908

United States

University of Washingont/Harborview Medical Center

Seattle, Washington 98104

United States